19 September 2022
Rules of import and export of biomaterials produced during clinical trials of drugs become effective in Russia from September 1 and will expire on September 1, 2028. The relevant Cabinet decree was posted on the official web portal of legal information, – TASS reported.
Rules stipulate that developers of pharmaceuticals, legal entities authorized by them to perform studies, research and educational institutions with their activities providing for the possibility of participating or organizing studies, can import or export biomaterials from Russia.
Organizations should submit an application to the Ministry of Health in order to receive the relevant conclusion. The application should contain details of the trial and its objectives, the name of the state and the entity for planned import or export of biomaterials, and information about such materials and their quantity. Incomplete submission of documents or unreliable data in them can be the cause to turn down import or export of biomaterials.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024